Clinical Research: Fabuless™ (FERNSlim's main ingredient) opens up exciting possibilities for manufacturers to develop a number of different innovative solutions for a range of consumer groups. Unlike many other weight management solutions, Fabuless™ does not rely on considerable individual effort and discipline. It has been designed simply to support people control their food intake and maintain a healthy diet. Independent extensive clinical data show that people using Fabuless™ eat less and often don’t even feel the difference - an interesting proposition for the consumer if it simply involves incorporating a tasty yoghurt with 5 grams Fabuless™ into the daily diet. For intensive dieting, a completely different but relevant concept could be developed by means of a ‘meal replacement shake, incorporating an active dose of, for example, 10 grams Fabuless™, to help reduce hunger feelings for those who normally have problems sticking to diets. Fabuless™ affects the amount of time it takes to become hungry again after a meal and how much food is eaten at the next meal. Our research shows that different fats, especially when structured and formulated in a specific way, each have a different effect on prolongation of satiety. The clinical evidence behind Fabuless™ is extensive. Four independent studies have been performed at the Northern Ireland Centre for Diet and Health at the University of Ulster. All studies consistently substantiate the product's effect on reducing calorie intake. The results of the studies show a reduction in calorie intake at subsequent meals between 12.5 to 29 percent. The effect has been shown to last for more than eight hours. These results have been published in three articles in scientific peer-reviewed journals. References: - International Journal of Obesity (2000) 24, 1419-1425 - International Journal of Obesity (2001) 25, 1487-1496 - European Journal of Clinical Nutrition (2002) 56, 368-377 ========================= Fabuless clinical trial boosts DSM By Stephen Daniells, 04-May-2007 DSM has announced its Fabuless ingredient (FERNSlim's main ingredient. FERN Slim is manufactured by DSM Sweden exclusively to FERN, Inc.) stopped weight gain after weight loss when consumed in yoghurt during a clinical trial, bolstering the product's initial success on the market. The study, a randomised, placebo-controlled and double-blind trial, adds significant support to the weight management potential of Fabuless, said to work by encapsulating particles of palm oil in oats, which are then formulated in a novel emulsion. The slow digestion of the oat fraction enables Fabuless to penetrate deeply into the intestinal system and, since digestion is delayed, it sends a message of fullness to the brain. With 50 per cent of Europeans and 62 per cent of Americans classed as overweight, the food industry is waking up to the potential of products for weight loss and management. The category already estimated to already be worth $7bn worldwide. "Consumption of [Fabuless] yoghurt improved weight maintenance compared to placebo, which can be explained by the relatively higher resting energy expenditure (REE) as a function of fat-free mass (FFM), relatively higher decrease in fat mass (FM) and the relatively lower increase in hunger," wrote the recent study's lead author Kristel Diepvens from Maastricht University. The work, published in the International Journal of Obesity, recruited 50 overweight women (BMI between 25 and 32 kgper sq. m) aged between 18 and 58 years, and assigned them to an initial six-week weight loss period followed by either a daily Fabuless-containing yoghurt or placebo for 18 weeks. Throughout, the subjects were weighed and measured according to height, body mass index (BMI), waist and hip circumference (weeks 2, 8, and 26). Satiety was evaluated using questionnaires and blood samples for analysis of satiety hormones at weeks 1, 7 and 25. The researchers report that, after the initial weight loss stage, the placebo group regained an average of three kilograms. On the other hand, consumption of the Fabuless supplement was not associated with a significant increase in body weight (gain of 1.1 kg) Self-reporting of satiety also showed that, compared to the placebo group, the Fabuless group was less hungry four hours after yoghurt consumption at the end of the study. An increase in the glucagon like peptide-1 (GLP-1) values two hours after yoghurt consumption was also observed for this group. The hormone GLP-1 is reported to work by delaying the emptying of the stomach (gastric emptying) and thereby promoting the feeling of fullness. Diepvens also reports that resting energy expedntiture as a function of fat-free mass was significantly higher than predicted for the Fabuless, but not for the placebo, group. Fat mass also significantly decreased more for the test group than placebo (6.5 versus 4.1 kg). Philip Rijken, head of nutritional science at DSM Food Specialties' Fabuless said the company was delighted with the results. "Regaining weight following weight loss is a key issue for consumers. After investing in a weight loss plan, consumers do not want to experience quick weight regain. This research is a good indication that with Fabuless it may be possible to achieve longer-term results. Offering extensive scientific proof, Fabuless is a strong proposition for manufacturers looking to create innovative weight management products to better support consumers." The ingredient was recently commended at the First International Conference on Innovations and Trends in Weight Loss and Weight Management in Berlin. Source: International Journal of Obesity Published on-line ahead of print, doi: 10.1038/sj.ijo.0803532 "Long-term effects of consumption of a novel fat emulsion in relation to body-weight management" Authors: K. Diepvens, S. Soenen, J. Steijns, M. Arnold, M. Westerterp-Plantenga. |
Clinical Research |